Precision medicine for multiple myeloma: The case for translocation (11;14)

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• The t(11;14) translocation is a common cytogenetic abnormality in multiple myeloma (MM).
• Its prognostic significance has evolved over time, from favorable to intermediate risk.
• This subtype exhibits unique biological features and treatment response patterns.

Purpose of the Study:

• To review the current evidence on the t(11;14) translocation in multiple myeloma.
• To explore its changing prognostic implications and biological characteristics.
• To discuss treatment sensitivities and future therapeutic strategies.

Main Methods:

• Literature review of existing research on t(11;14) multiple myeloma.
• Analysis of studies examining prognostic significance and treatment responses.
• Synthesis of data regarding biological features and therapeutic vulnerabilities.

Main Results:

• The t(11;14) translocation has shown variable prognostic value.
• This MM subtype is less responsive to proteasome inhibitors and immunomodulatory drugs.
• t(11;14) MM demonstrates heightened sensitivity to venetoclax due to Bcl-2 dependency.

Conclusions:

• Further subclassification of t(11;14) MM using genomic and morphologic data is needed.
• Improved prediction models can enable tailored therapeutic strategies.
• Understanding t(11;14) biology is crucial for optimizing MM treatment.